HC Wainwright Forecasts Armata Pharmaceuticals Q3 Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Armata Pharmaceuticals from **($0.50)** to **($0.42)**, maintaining a "Buy" rating and a target price of **$9.00**.
• Armata Pharmaceuticals has a market cap of **$92.39 million** and its stock is currently trading at **$2.55**, with a 12-month range between **$0.90** and **$2.96**.
• GSB Wealth Management recently acquired **30,000 shares** of Armata Pharmaceuticals, representing **0.08%** ownership of the company, highlighting interest from institutional investors.

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for shares of Armata Pharmaceuticals in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.42) for the quarter, up from their previous forecast of ($0.50). HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Armata Pharmaceuticals' current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Armata Pharmaceuticals' Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.46) EPS.

Armata Pharmaceuticals Stock Performance

ARMP stock traded down $0.03 during trading on Friday, hitting $2.51. The company had a trading volume of 11,761 shares, compared to its average volume of 105,851. The firm has a market cap of $90.94 million, a PE ratio of -2.44 and a beta of 0.99. The stock has a 50-day moving average price of $2.25. Armata Pharmaceuticals has a one year low of $0.90 and a one year high of $2.96.

Hedge Funds Weigh In On Armata Pharmaceuticals

A hedge fund recently bought a new stake in Armata Pharmaceuticals stock. GSB Wealth Management LLC bought a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals as of its most recent SEC filing. 3.57% of the stock is owned by institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.